Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors

Journal of Clinical Oncology

Volumn 20, Issue 8, 2002, Pages 2157-2170

  Schwartz, Gary K ^a   O'Reilly, Eileen ^a   Ilson, David ^a   Saltz, Leonard ^a   Sharma, Sunil ^a   Tong, William ^a   Maslak, Peter ^a   Stoltz, Maxine ^a   Eden, Larry ^a   Perkins, Pam ^a   Endres, Sandra ^a   Barazzoul, John ^a   Spriggs, David ^a   Kelsen, David ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; ESOPHAGUS CANCER; FEMALE; HUMAN; LUNG CANCER; LUNG TOXICITY; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SOLID TUMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLIN-DEPENDENT KINASES; FEMALE; FLAVONOIDS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; PIPERIDINES;

EID: 0037089691     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.08.080     Document Type: Article

References (32)

1. An anti-inflammatory cum immunomodulatory piperidinylbenzopyranone from dysoloxylum binectiferum: Isolation, structure and total synthesis
2. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase CDK2 and CDK4 in human breast carcinoma cells
3. Potent inhibition of cdc2 kinase activity by the flavonoid L86-8275
4. Alteration of the phosphorylation state or p34cdc2 kinase by the flavone 186-8275 in breast carcinoma cells
5. Down-regulation of cyclin DI by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol
6. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication
7. The cyclin-dependent kinase inhibitor flavopiridol inhibits glycogen phosphorylase
8. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275
9. Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridol
10. Flavopiridol: A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells
11. Phase I clinical and pharmacokinetic trial of flavopiridol
12. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor in patients with refractory neoplasms
13. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago phase II consortium study
14. A phase II study of the cyclin dependent kinase inhibitor flavopiridol administered in patients with advanced gastric carcinoma
15. Phase II trial of flavopiridol in metastatic colorectal cancer: Preliminary results
16. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer
17. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells
18. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration
19. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with downregulation of ribonucleotide reductase M2 subunit
20. Augmentation of apoptosis and tumor regressions by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts
21. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer
22. Strategies for phenotyping apoptotic peripheral human lymphocytes comparing ISNT, annexin-V, and 7-AAD cytofluorometric staining methods
23. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines
24. Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver
25. Flavopiridol (NSC649890) pharmacokinetics suggests enterohepatic circulation
26. Plasma and urinary kinetics of the isoflavones daidzein and genistein after a single soy meal in humans
27. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea
28. Activity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus
29. Potentiation of apoptosis by flavopiridol on mitomycin-c treated gastric and breast cancer cells
30. Docetaxel and Navelbine induced apoptosis is enhanced by flavopiridol (Flavo) in breast cancer cells and is sequence dependent
31. Phase I trial of sequential paclitaxel and cisplatin in combination with the cyclin dependent kinase inhibitor flavopiridol in patients with advanced solid tumors
32. A phase I trial of 1 hour flavopiridol, a novel cyclin dependent kinase inhibitor, in patients with advanced neoplasms